European Primary Care Cardiovascular Society

New diagnostic strategy to improve early CVD diagnosis in primary care patients with COPD or T2D

3' education - Oct. 11, 2023 - Amy Groenewegen, MD

Benefit with bempedoic acid in reducing total incidence of MACE

3' education - Oct. 9, 2023 - Stephen Nicholls, MD

CVD impacts all areas of the economy

3' education - Oct. 9, 2023 - Iris Harmsen, MD and Ramón Luengo-Fernandez, PhD

Ferric carboxymaltose as another tool in the toolkit for patients with HF and iron deficiency

3' education - Oct. 9, 2023 - Robert Mentz, MD

Unique randomized withdrawal heart failure trial with SGLT2i

3' education - Oct. 9, 2023 - Milton Packer, MD

Clinically meaningful benefits with GLP-1RA in patients with HFpEF and obesity

3' education - Oct. 9, 2023 - Mikhail Kosiborod, MD

Unexpected results after switching from VKA to DOAC in older frail patients with AF

3' education - Oct. 9, 2023 - Linda Joosten, MD

Benefits of rapid uptitration of HF medications independent of baseline renal function

3' education - July 13, 2023 - Jozine ter Maaten, MD, PhD

ARNI superior to ARB in reducing NT-proBNP in patients with HFmrEF/HFpEF

3' education - July 13, 2023 - Robert Mentz, MD

Remote hemodynamic monitoring improves quality of life and reduces HF hospitalizations in HF

3' education - July 13, 2023 - Jasper Brugts, MD, PhD

Regional differences in prescription of PCSK9i therapy across Europe

10' education - July 12, 2023 - Maciej Banach, MD, PhD

The right therapy for the right patient

3' education - June 26, 2023 - Stephen Nicholls, MD

Elevated inflammation markers in diabetes: a cause or a consequence?

3' education - June 26, 2023 - Peter Libby, MD

How to manage patients with elevated Lp(a)

3' education - June 26, 2023 - Florian Kronenberg, MD, PhD

Relevance of adipose tissue in cardio-metabolic complications

3' education - June 26, 2023 - Antonio Vidal-Puig, MD

Fitting in bempedoic acid in the arsenal of lipid-lowering therapies

3' education - Mar. 30, 2023 - Prof. Kausik Ray, MD

Lowering LDL-c and CV risk with new evidence-based non-statin treatment

3' education - Mar. 18, 2023 - Prof. Peter Libby, MD

No association of early eGFR decline after transitioning to ARNI with adverse outcomes

3' education - Mar. 14, 2023 - Safia Chatur, MD

A phase 3 trial with bempedoic acid: Strengths and limitations

3' education - Mar. 13, 2023 - Prof. Eugene Yang, MD

Low-carbohydrate high-fat diet is associated with CV events

3' education - Mar. 11, 2023 - Liam Brunham, MD, PhD

Elderly people also benefit from lipid-lowering therapy for primary prevention

Literature - Nov. 29, 2023 - Andersson NW, et al. - J Am Coll Cardiol. 2023

In a Danish cohort study, individuals aged ≥70 years achieved a similar relative risk reduction of major vascular events with lipid-lowering therapy for primary prevention of CVD as those aged <70 years.

GLP-1RA reduces CV outcomes in patients with overweight or obesity without diabetes

News - Nov. 28, 2023

AHA 2023 In the SELECT trial, subcutaneous semaglutide 2.4 mg once weekly reduced the risk of CV events in patients with preexisting CVD and overweight or obesity who do not have diabetes.

DOAC reduces stroke in patients with subclinical atrial fibrillation

News - Nov. 28, 2023

AHA 2023 Apixaban reduced stroke or systemic embolism in patients with subclinical atrial fibrillation compared with aspirin in the ARTESIA trial. Apixaban increased the risk of major bleeding but there was no increase intracranial bleeding or fatal bleeding.

BP lowering reduces dementia in patients with hypertension

News - Nov. 28, 2023

AHA 2023 In the absence of curative therapies for dementia, it was investigated whether a BP-lowering intervention can reduce the risk of dementia in patients with hypertension in China.

Low-sodium diet significantly lowers SBP within a week

News - Nov. 28, 2023

AHA 2023 In middle-aged individuals, a low-sodium diet significantly lowered SBP already within a week compared to the participants’ usual diet. The SBP reduction was independent of anti-hypertensive medication use and hypertension status.

Optimizing postpartum anti-hypertensive therapy improves long-term BP control after hypertensive pregnancy

News - Nov. 28, 2023

AHA 2023 In the POP-HT trial, self-monitoring of BP in combination with physician guided anti-hypertensive medication adjustment during the first 6 weeks postpartum led to improvements in BP up to 9 months after a hypertensive pregnancy.

High and increasing prevalence of cardio-renal-metabolic multimorbidity

Literature - Oct. 23, 2023 - Ostrominski JW, et al. - JAMA Cardiol. 2023

A population-based cohort study showed that cardio-renal-metabolic conditions (CVD, CKD, and T2D) and their overlap were increasingly common among US adults over the last 2 decades.

Discontinuation of dual GIP and GLP-1 receptor agonist leads to weight regain in people with obesity or overweight

News - Oct. 16, 2023

EASD 2023 In the SURMOUNT-4 trial, patients on 36-weeks of treatment with tirzepatide at maximally tolerated doses (10 mg or 15 mg) were randomized to continued therapy or discontinuation of therapy with placebo to assess whether body weight reductions by tirzepatide are maintained in people with obesity or overweight.

Effects of GLP-1RA on top of SGLT2 inhibitor on albuminuria in patients with T2D and albuminuria

News - Oct. 11, 2023

EASD 2023 A small randomized study showed that treatment with GLP-1RA semaglutide on top of empagliflozin did not have an additional beneficial effect on albuminuria in patients with T2D and albuminuria compared with placebo.

Treatment effect of SGLT2i across background of glucose-lowering therapies in T2D and HFmrEF/HFpEF

News - Oct. 11, 2023

EASD 2023 In patients with T2D and HFmrEF/HFpEF, the treatment effect of dapagliflozin on the primary outcome was consistent across the number and most types of baseline glucose-lowering therapies.

New diagnostic strategy to improve early CVD diagnosis in primary care patients with COPD or T2D

3' education - Oct. 11, 2023 - Amy Groenewegen, MD
**ESC Congress 2023** In the RED-CVD study, it was investigated whether a new diagnostic strategy could increase the number of new CVD diagnoses in primary care patients with COPD or T2D compared with usual care. Amy Groenewegen shares the results.

ESC Congress 2023 In the RED-CVD study, it was investigated whether a new diagnostic strategy could increase the number of new CVD diagnoses in primary care patients with COPD or T2D compared with usual care. Amy Groenewegen shares the results.

Benefit with bempedoic acid in reducing total incidence of MACE

3' education - Oct. 9, 2023 - Stephen Nicholls, MD
**ESC Congress 2023** Stephen Nicholls shares the results of the total events analysis of the CLEAR Outcomes trial. He compares the hazard ratios of the first event and total events analyses and explains the implications of these results.

ESC Congress 2023 Stephen Nicholls shares the results of the total events analysis of the CLEAR Outcomes trial. He compares the hazard ratios of the first event and total events analyses and explains the implications of these results.

Agenda